U.S. Digital Therapeutics Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on U.S. Digital Therapeutics Market 

5.1. COVID-19 Landscape: U.S. Digital Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact:  Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8.  U.S. Digital Therapeutics Market, By Application

8.1. U.S. Digital Therapeutics Market, by Application, 2024-2034

8.1.1 Diabetes

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Obesity

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Central Nervous System Diseases

8.1.3.1. Market Revenue and Forecast (2021-2034)

8.1.4. Cardiovascular Disease (CVD)

8.1.4.1. Market Revenue and Forecast (2021-2034)

8.1.5. Respiratory Disease

8.1.5.1. Market Revenue and Forecast (2021-2034)

8.1.6. Smoking Cessation

8.1.6.1. Market Revenue and Forecast (2021-2034)

8.1.7. Gastrointestinal Disorder (GID)

8.1.7.1. Market Revenue and Forecast (2021-2034)

8.1.8. Others

8.1.8.1. Market Revenue and Forecast (2021-2034)

Chapter 9.  U.S. Digital Therapeutics Market, By Product

9.1. U.S. Digital Therapeutics Market, by Product, 2024-2034

9.1.1. Software

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Device

9.1.2.1. Market Revenue and Forecast (2021-2034)

Chapter 10.  U.S. Digital Therapeutics Market, By End Use 

10.1. U.S. Digital Therapeutics Market, by End Use, 2024-2034

10.1.1. Patients

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. Providers

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Payers

10.1.3.1. Market Revenue and Forecast (2021-2034)

10.1.4. Employers

10.1.4.1. Market Revenue and Forecast (2021-2034)

10.1.5. Others

10.1.5.1. Market Revenue and Forecast (2021-2034)

Chapter 11.  U.S. Digital Therapeutics Market, Regional Estimates and Trend Forecast

11.1. U.S.

11.1.1. Market Revenue and Forecast, by Application (2021-2034)

11.1.2. Market Revenue and Forecast, by Product (2021-2034)

11.1.3. Market Revenue and Forecast, by End Use (2021-2034)

Chapter 12. Company Profiles

12.1. Omada Health Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. 2Morrow Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Teladoc Health, Inc

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Pear Therapeutics (U.S), Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Fitbit Health Solutions

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Welldoc, Inc

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Click Therapeutics

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Noom, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Akili, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Better Therapeutics, Inc

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms